SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-19-033927
Filing Date
2019-09-04
Accepted
2019-09-04 06:04:08
Documents
14
Period of Report
2019-09-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-8k_20190904.htm   iXBRL 8-K 38719
2 EX-99.1 rare-ex991_46.htm EX-99.1 65640
3 GRAPHIC gbdvquylgcvk000001.jpg GRAPHIC 348834
  Complete submission text file 0001564590-19-033927.txt   722723

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rare-20190904.xsd EX-101.SCH 6209
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20190904_lab.xml EX-101.LAB 19059
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20190904_pre.xml EX-101.PRE 11729
16 EXTRACTED XBRL INSTANCE DOCUMENT rare-8k_20190904_htm.xml XML 3414
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 191073248
SIC: 2834 Pharmaceutical Preparations